Navigation Links
Despite efforts, significant racial disparities in cancer therapy still exist
Date:1/7/2008

Black patients are significantly less likely than their white counterparts to receive therapy for various kinds of cancer, despite recent efforts to close gaps in treatment, according to a study by researchers at Yale School of Medicine published in the January 7 online issue of the journal Cancer.

Prior research revealed racial disparities in cancer care in the early 1990s. Cary P. Gross, M.D., associate professor of medicine at Yale School of Medicine, and colleagues studied the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to evaluate whether greater attention and investment in access to care for all individuals have led to any reduction in cancer treatment disparities. They evaluated patients in the SEER database who had been diagnosed with breast, colorectal, lung or prostate cancer between 1992 and 2002.

After identifying therapies for which racial disparities had been previously reported, the investigators determined whether there had been any changes in care for the overall Medicare population or for white and black patients considered separately. The team evaluated 7,775 colon, 1,745 rectal, 11,207 lung, 40,457 breast and 82,238 prostate cancer cases.

The team found that throughout the study period, black patients were significantly less likely than white patients to receive therapy for cancers of the lung, breast, colon and prostate. For both black and white patients, there were little or no improvements in the proportion of patients receiving therapy for most cancers. There was also no decrease in the magnitude of racial disparities between 1992 and 2002. These racial disparities persisted even after limiting the analysis to patients who had access to a physician prior to their cancer diagnosis.

The findings suggest that there has been little improvement in the overall proportion of Medicare beneficiaries receiving cancer care. They also reveal that racial disparities have not les
'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert  

0

GOOD

Page: 1 2

Related medicine news :

1. Coshocton County Memorial Hospital RNs to Strike Despite Hospitals Claim of Financial Hardship
2. Miscarriage myths persist despite prevalence of medical information
3. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
4. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
5. A Full and Long Life, Despite Diabetes
6. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
7. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
8. UGA study: Youth exposed to smokeless tobacco ads despite settlement
9. Cataract Surgery: A Bargain, Despite the Price
10. Most patients who have male-to-female sex-change surgery are happy, despite complications
11. Despite grumbling, most Americans say they are happy at work

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Despite efforts, significant racial disparities in cancer therapy still exist
Despite efforts, significant racial disparities in cancer therapy still exist
(Date:12/2/2009)...LE, Tenn., Dec. 2 TeamHealth ( www...t Florida with the acquisition of Naples-based Eme...uary 2002, EPN has held an exclusive contract with...lities at the Downtown Naples Hospital, North Napl...also provides the staffing for two stand-alone urg...
(Date:12/2/2009)...he official congress of the European Association o...he European Society of Cardiology, where technique...nted. , New case reports will be presented at t...lighting the role of this new technology. , Now...s, it is likely that non-invasive imaging will gai...
(Date:12/2/2009)... Revolutionary new cell phones that direct mi...be available in early 2010 from Aerius Internation...er 2, 2009 -- Revolutionary new cell phones that d...rs will be available in early 2010 from Aerius Int...d with a Green Technology Award in wireless commun...
(Date:12/2/2009)... Dec. 2 The American He... Directors today announced Alan F. Dowling, PhD, w...er health information management (HIM) leader. Dr...e includes academia, systems management, strategic...rofit executive leadership. He is scheduled to ta...
(Date:12/2/2009)...Today,s Washington Post Highlights Dangers ...- If the Catholic bishops have their way, many ...ke for granted may be under threat. The pressure ...bate over healthcare reform has been widely report...s of the likely impact if that pressure to influen...
Breaking Medicine News(10 mins):Health News:TeamHealth Acquires Emergency Physicians of Naples, LLC 2Health News:Media alert: EUROECHO 2009 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
...Products offer biologically safe water through poi...on, NEW YORK, June 3 Nephros, Inc., a medical,de...biting its Dual Stage,Ultrafilter products at the ...ss of the Nephros online,hemodiafiltration technol...
..., N.J., June 3 BD (Becton,Dickinson and Company) ...,announced today that it would present at the Gold...nference on Wednesday, June 11, 2008, at 4:20,p.m....r replay,through Wednesday, June 18, 2008., BD, a...
...N.J., June 3 HLTH Corporation,(Nasdaq: HLTH ) to...e,agreement to sell its ViPS segment to General Dy...d subsidiary of General Dynamics Corporation,(NYSE...d under the Hart-Scott-Rodino Act., ViPS provides...
...ells can produce tiny magnetic nuggets after the i...ists have found. The gene MagA could become a valu... body via magnetic resonance imaging (MRI), says X...to make mammalian cells have a magnetic signature,...
...., June 3 MedAmerica reports 2007 was its,17th co...sults. In,addition, MedAmerica outperformed the lo...years with a compound annual sales rate of 10%. (L...America,Insurance Company of Florida (Home Office:...
...June 3 On June 7, 2008 the Philadelphia,Physician...hensive,physicals for student athletes in the Phil...sylvania are required to receive a physical to be ...life-threatening conditions., The 2008 program wi...
Other Medicine News:Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 2Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 3Health News:Nephros Exhibiting at Denver, Colorado APIC Conference June 15th-19th 4Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 2Health News:HLTH Announces Agreement to Sell ViPS Unit to General Dynamics for $225 Million 3Health News:Philly's Top Doc's Organize to Help Prevent Young Athlete Deaths in Philadelphia 2
(Date:12/2/2009)..., PLEASANTON, Calif., Dec. 2 /PRNewswire-FirstCal... today that the United States Food & Drug Admi...se for its licensed nucleic acid test, to screen s...dual donations. The test, called the cobas® T...tem, is a qualitative, in-vitro test for the simul...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewswire/...ing a late-breaking presentation on Tasigna® ...yeloid leukemia, demonstrate the strength of the c...e of patients. ,, The new data, at the 51st Am...and Exposition, highlight the company,s current th...
(Date:12/1/2009)..., REDONDO BEACH, Calif., Dec. 1 Re...their Elective Single Embryo Transfer (eSET) Encou...for patients with good embryo quality and a good p...ce of twins by transferring a single embryo. ,,...logy today is reducing the number of multiple preg...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Reproductive Partners Announces Elective Single Embryo Transfer (eSET) Encouragement Program 2Craneware Announces Fiscal Year End Results 56424 1Craneware Announces Fiscal Year End Results 56424 2Craneware Announces Fiscal Year End Results 56424 3Dr Smith Comes to Washington 3A Angry Physicians From All 50 States Rally in DC on Sept 10 56422 1Dr Smith Comes to Washington 3A Angry Physicians From All 50 States Rally in DC on Sept 10 56422 2Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 1Bipartisan Policy Center and Better Health Care Together to Host Joint Health Care Forum Tomorrow 56420 2
...all at 9:00 AM ET Today , , CORAL GABLES, Fla.,...asdaq: CPRX ) today announced top-line results f...ine addiction. The data from the trial showed tha...ance in the primary endpoint -- that a significant...han placebo-treated subjects were cocaine-free dur...
...nd Evidence of Biological Activity in 9 of 12 Pati...7 Leading U.S. Medical Centers , , SAN DIEGO, May...data from the Calcium Up-Regulation by Percutaneou...e (CUPID), a First-in-Human Phase 1/2 Clinical Tri...merican Society of Gene Therapy Meeting. , , Th...
Other Medicine Technology:Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 2Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 3Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction 4Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting 2Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting 3Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting 4
...ual acuity system allows you access to the most po...s 10 different optotypes, crowding bars, random se...d characters. Random character sequencing eliminat...gle letter, single line and multiple line selectio...
...ght Probes provide the surgeon with an indirect il...e to be easily visualized through the laser micros...catter technique, the surgeon can enhance visualiz...ap edge folds, corneal flap striae and flap alignm...
...ual acuity system allows you access to the most po...s 10 different optotypes, crowding bars, random se...d characters. Random character sequencing eliminat...gle letter, single line and multiple line selectio...
...channel sleep diagnostic collection software. Sand...eep diagnostic collection software offers customiz...t recording or post recording. The scoring display...p events including current number of events, frequ...
Medicine Products: